Likewise, miRNA-146 administered from MSC-EVs has been found to inhibit microglial neuroinflammation by inhibiting TRAF6 and IL-1 receptor-related kinase 1 in microglia in patients with Alzheimer’s disease [46]. Here, TRAF6 is linked to early-onset autosomal dominant Alzheimer disease.